Nuwellis, INC 8-K filings

Nestor Jaramillo, Jr. retires as President and CEO of Nuwellis, Inc., with John Erb appointed as Interim President and CEO, effective February 18, 2025.

Nuwellis, Inc. has successfully regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, ensuring its continued listing on the Nasdaq Capital Market.

Nuwellis, Inc. has voluntarily recalled specific lots of its AquaFlexFlow UF 500 Plus blood circuits due to failures causing mismatch alarms and potential patient dehydration.

Nuwellis reported a slight decrease in revenue for Q3 2024, but highlighted a substantial CMS reimbursement increase and strong growth in pediatrics revenue.

Nuwellis, Inc. has generated $5.1 million in gross proceeds through the exercise of existing warrants and issued new warrants as part of an inducement offer.

Nuwellis announced preliminary third-quarter 2024 results, highlighting revenue of approximately $2.4 million, a 28% growth in the pediatric sector, and a significant improvement in gross margin to 70%.

Nuwellis, Inc. and SeaStar Medical Holding Corporation have terminated their distribution agreement, with SeaStar agreeing to pay Nuwellis $900,000 to settle the dispute.

Nuwellis, Inc. has announced a registered direct offering of common stock and warrants to raise approximately $916,000 for working capital and general corporate purposes.

Nuwellis, Inc. and DaVita Inc. have mutually agreed to terminate their Supply and Collaboration Agreement, effective immediately, along with related agreements.

Nuwellis, Inc. announced a 6% revenue increase in the second quarter of 2024, driven by strong growth in critical care and heart failure consumables, alongside significant cost reductions.

Nuwellis, Inc. has been granted continued listing on the Nasdaq, contingent on demonstrating compliance with the Stockholders Equity Requirement by filing its Q3 2024 report.

Nuwellis, Inc. has announced the pricing of a $2.0 million offering consisting of a registered direct offering of common stock and a concurrent private placement of warrants.

Nuwellis Inc. has updated its corporate presentation and revised risk factors related to off-label use of its Aquadex system.

Nuwellis, Inc. has announced its first commercial sale of QUELIMMUNE therapy to Cincinnati Children's Hospital, marking a significant step in pediatric critical care.

Nuwellis, Inc. released an updated corporate presentation and revised a risk factor related to off-label product use in a recent SEC filing.

Nuwellis, Inc. has terminated its At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc., effective July 9, 2024, ceasing further issuance of common stock under the agreement.

Nuwellis, Inc. has announced a 1-for-35 reverse stock split of its common stock, effective June 27, 2024, to be traded on a split-adjusted basis starting June 28, 2024.

Nuwellis, Inc. received a delisting notice from Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements, while also securing approval for a reverse stock split at its annual meeting.

Nuwellis and DaVita have extended their pilot program for the Aquadex ultrafiltration therapy system to August 31, 2024, to further evaluate its use in treating adult patients with congestive heart failure.

Nuwellis, Inc. received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement, placing its listing status at risk.

Nuwellis, Inc. announced a 2% revenue increase and improved gross margins for the first quarter of 2024, driven by strong growth in consumables and pediatric sales.

Nuwellis, Inc. successfully closed a public offering, raising approximately $2.7 million through the sale of common stock and warrants.

Nuwellis Inc. filed a Form 8-K to replace the business overview section of its 2023 annual report, emphasizing its focus on ultrafiltration technology for fluid overload.

Nuwellis, Inc. announced its fourth quarter and full year 2023 financial results, highlighting record quarterly revenue, strong pediatric sales growth, and expanding gross margins.

Nuwellis, Inc. released new data demonstrating the potential of its Aquadex SmartFlow system for treating fluid overload in patients with end-stage liver disease.